AKT1 and prostate carcinoma: This drug stimulates autophagosome formation by downregulating the AKT/mTOR pathway and inhibits the autophagic flux by increasing lysosomal pH and affecting autolysosomal maturation in LNCaP prostate carcinoma cells45.